• LAST PRICE
    0.0030
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 0.0030
  • Day Range
    ---
  • 52 Week Range
    Low 0.0030
    High 0.0030
  • Volume
    ---

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
Table Data Not Available
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesVOQP
Vioquest Pharmaceuticals Inc
43.1K
0.0x
---
United StatesLIFS
Life Stem Genetics Inc
18.3K
0.0x
---
United StatesCTBO
Cantabio Pharmaceuticals Inc
22.8K
0.0x
---
United StatesMYRX
Myrexis Inc
34.5K
0.0x
---
United StatesARYX
ARYx Therapeutics Inc
16.7K
0.0x
---
United StatesFPMI
FluoroPharma Medical Inc
58.3K
0.0x
---
As of 2023-02-04

Company Information

VioQuest Pharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of clinical stage drug therapies targeting both the molecular basis of cancer and side effects of cancer treatment. The Company’s lead compound under development is Xyfid (1% topical uracil) for the treatment and prevention of Hand-Foot Syndrome (HFS). In parallel, Xyfid is also being developed to treat dry skin conditions and manage the burning and itching associated with various diseases of the skin or dermatoses. In addition, VioQuest Pharmaceuticals is developing VQD-002 (triciribine phosphate monohydrate or TCN-P), a small molecule anticancer compound that inhibits activation of protein kinase B (PKB or AKT), a key component of a signaling pathway known to promote cancer cell growth and survival, as well as resistance to chemotherapy and radiotherapy. On July 16, 2007, the Company completed the sale of Chiral Quest, Inc. to Chiral Quest Acquisition Corp.

Contact Information

Headquarters
180 Mount Airy Rd Ste 102BASKING RIDGE, NJ, United States 07920-2064
Phone
732-274-0399
Fax
302-655-5049

Executives

Chief Financial Officer, Vice President
Christopher Schnittker
Vice President - Research & Development
Vernon Alvarez
Director
Johnson Lau
Director
Wayne Mills

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$43.1K
Revenue (TTM)
$0.00
Shares Outstanding
5.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.32
Book Value
$-0.82
P/E Ratio
0.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.